CN1126558C - Medicine for treating kidney damage caused by immunological disease lupus erythematosus - Google Patents
Medicine for treating kidney damage caused by immunological disease lupus erythematosus Download PDFInfo
- Publication number
- CN1126558C CN1126558C CN 01104489 CN01104489A CN1126558C CN 1126558 C CN1126558 C CN 1126558C CN 01104489 CN01104489 CN 01104489 CN 01104489 A CN01104489 A CN 01104489A CN 1126558 C CN1126558 C CN 1126558C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- lupus erythematosus
- kidney damage
- damage caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating kidney damage caused by the immunological disease of lupus erythematosus. The medicine is prepared from the traditional Chinese medicines prepared in ready-to-use forms of tree peony bark, astragalus root, rehmannia root, ginseng, desertliving cistanche, cornel, kudzuvine root, schisandra fruit, smoked plum, water plantain, phellodendron bark, cassia bark, catclaw buttercup root, serisa, centella, williams elder twig, etc. according to a specific technology. The medicine of the present invention has a very good effect on treating kidney damage caused by the immunological disease of lupus erythematosus, and does not have any toxic and side effect.
Description
The present invention relates to a kind of medicine that kidney that lupus erythematosus causes decreases for the treatment of.Be specifically with the Chinese herbal medicine be raw material according to the Chinese patent medicine that certain prepared forms, belong to the field of Chinese medicines.
Systemic lupus erythematosus (sle) is that world's medical matters circle are referred to as one of four big difficult disease of wrecking the human life, and domestic and international interrelated data report, the sickness rate that every year should disease to be rapidly increasing progressively by a relatively large margin, to the mankind's threat not second to cancer and acquired immune deficiency syndrome (AIDS).In areas such as the Luo Qisite of the U.S., California, the sickness rate in its members of the same clan exceeds hundreds of times of general crowd up to 0.4-5%.Black people's sickness rate is three times in general crowd, and in the Black women of 15-45, per 245 people have a people to suffer from lupus erythematosus, is more common in the 15-25 young women in year especially.Before not using the 17-hydroxy-11-dehydrocorticosterone treatment, the primary disease mortality rate is very high, 80% patient dies from primary disease in 2 years, in recent years because the progress of diagnostic techniques and utilization 17-hydroxy-11-dehydrocorticosterone, the utilization of immunosuppressant, levamisole, antiviral drugs, antilymphocyte globulin thymosin and Chinese herbal medicine, the primary disease mortality rate progressively descends, and best survival rate has reached 80-85% in present 10 years.Though change is arranged, but, still have the part patient to die from organa parenchymatosums such as the heart, kidney, the brain infringement and the complication of primary disease because of various factors, hormone and the immunosuppressant of using both at home and abroad brought potential infection and transition to use this type of medicine to suppress the normal immunologic function of body to patient at present, destroyed organism balance, the patient is caused a disease because of lupus erythematosus, is exactly to cause death because of side effects of pharmaceutical drugs.Particularly, systemic lupus erythematosus (sle) is the autoimmune disease that causes multiple organ injury, and the most common with the infringement to kidney especially, almost 100% Patients with SLE kidney is invaded.At present still there is not effective medicine can be used for the treatment of the kidney damage of Patients with SLE clinically.Bring very big misery to patient, the patient's of crisis constantly life.
The object of the invention provides a kind of medicine of therapy system lupus erythematosus patient kidney damage.
Medicine of the present invention is that the Chinese herbal medicine by the following weight proportioning forms according to certain prepared:
Cortex Moutan 15-20
Radix Astragali 12-18
Radix Rehmanniae 9-12
Radix Ginseng 5-9
Herba Cistanches 12-18
Fructus Corni 9-12
Radix Puerariae 4-8
Fructus Schisandrae Chinensis 3-7
Rhizoma Alismatis 3-7
Rhizoma Alismatis 3-7
Cortex Phellodendri 3-7
Fructus Mume 3-7
Cortex Cinnamomi 2-5
Radix Ranunculi Ternati 5-10
Serissa foetida 8-15
Herba sambuci chinensis 15-20
Ramulus Sambuci Williamsii 12-18
Medicine of the present invention preferably is prepared from by the Chinese medicine of following weight parts:
Cortex Moutan 18
The Radix Astragali 15
The Radix Rehmanniae 10
Radix Ginseng 7
Herba Cistanches 15
Fructus Corni 10
Radix Puerariae 5
Fructus Schisandrae Chinensis 5
Rhizoma Alismatis 5
Cortex Phellodendri 5
Fructus Mume 5
Cortex Cinnamomi 3
Radix Ranunculi Ternati 7
Serissa foetida 10
Herba sambuci chinensis 17
Ramulus Sambuci Williamsii 15
Medicine of the present invention can be prepared into pharmaceutical dosage form commonly used clinically according to common process, preferred capsule.
Medicine of the present invention is on raw material is formed, and compatibility is reasonable, the Radix Astragali, Radix Ginseng supplementing QI to prevent collapse, and the Radix Rehmanniae, Cortex Moutan nourishing YIN and clearing heat are enriched blood and are invigorated blood circulation, Fructus Corni, Herba Cistanches, Fructus Schisandrae Chinensis, Fructus Mume invigorating the liver and kidney benefiting essence-blood astringent therapy astringency inducing, Rhizoma Alismatis, Cortex Phellodendri expel the heat-evil, promoting diuresis to eliminate damp pathogen.Radix Ranunculi Ternati, Serissa foetida, Herba sambuci chinensis, Ramulus Sambuci Williamsii are share the heat clearing and blood circulation promoting diuretic, to control the albumen hematuria.Radix Puerariae, Cortex Cinnamomi are agitated kidney yang, rise and send out clear the moon, inspire the source of the gas of the clear the moon of taste with filling life.All medicines share, and QI invigorating rises cloudy the kidney invigorating astringency inducing, to reach the purpose of recovering the kidney merit.With the medicine that this composition is made, can obviously improve the permeability of glomerular basement membrane blood capillary, reduce and the elimination urine protein, to reducing blood urea nitrogen, creatinine, improving CO2 combining power, CO2 CP has effect preferably, and zoopery confirms, medicine lupus kidney peaceful 0.35 of the present invention, 1.05,3.15g/kg or 0.65,1.95,5.85g/kg, C-s13A is caused rabbit nephritis and rat Heym2nn nephritis all has certain preventive and therapeutic effect, for its clinical treatment lupus nephritis provides competent pharmacology's foundation.Be used for the treatment of 3157 routine lupus nephropathy people clinically, its effective percentage reaches 91.76%.The present invention fills up this blank for international medical market provides a good effect, treatment lupus kidney new drug without any side effects.
Embodiment:
Choose raw material according to following composition
Cortex Moutan 18
The Radix Astragali 15
The Radix Rehmanniae 10
Radix Ginseng 7
Herba Cistanches 15
Fructus Corni 10
Radix Puerariae 5
Fructus Schisandrae Chinensis 5
Rhizoma Alismatis 5
Cortex Phellodendri 5
Fructus Mume 5
Cortex Cinnamomi 3
Radix Ranunculi Ternati 7
Serissa foetida 10
Herba sambuci chinensis 17
Ramulus Sambuci Williamsii 15
With said medicine, pick up decontamination, clean, add water and do not have powder, decoct twice, each 1 hour, merge decoction liquor twice, concentrate fluid extract, add appropriate amount of starch, pelletize, tabletting promptly makes tablet.
Claims (3)
1, a kind of medicine for the treatment of the caused by lupus erythematosus kidney damage is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Cortex Moutan 15-20
Radix Astragali 12-18
Radix Rehmanniae 9-12
Radix Ginseng 5-9
Herba Cistanches 12-18
Fructus Corni 9-12
Radix Puerariae 4-8
Fructus Schisandrae Chinensis 3-7
Rhizoma Alismatis 3-7
Cortex Phellodendri 3-7
Fructus Mume 3-7
Cortex Cinnamomi 2-5
Radix Ranunculi Ternati 5-10
Serissa foetida 8-15
Herba sambuci chinensis 15-20
Ramulus Sambuci Williamsii 12-18
2, medicine according to claim 1 is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Cortex Moutan 18
The Radix Astragali 15
The Radix Rehmanniae 10
Radix Ginseng 7
Herba Cistanches 15
Fructus Corni 10
Radix Puerariae 5
Fructus Schisandrae Chinensis 5
Rhizoma Alismatis 5
Cortex Phellodendri 5
Fructus Mume 5
Cortex Cinnamomi 3
Radix Ranunculi Ternati 7
Serissa foetida 10
Herba sambuci chinensis 17
Ramulus Sambuci Williamsii 15
3, medicine according to claim 1, the dosage form that it is characterized in that this medicine is a tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01104489 CN1126558C (en) | 2001-02-27 | 2001-02-27 | Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01104489 CN1126558C (en) | 2001-02-27 | 2001-02-27 | Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1310011A CN1310011A (en) | 2001-08-29 |
| CN1126558C true CN1126558C (en) | 2003-11-05 |
Family
ID=4653945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01104489 Expired - Fee Related CN1126558C (en) | 2001-02-27 | 2001-02-27 | Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1126558C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100682046B1 (en) | 2005-03-30 | 2007-02-12 | 정두수 | Herbal extract for treating lupuse |
| CN102698069B (en) * | 2012-07-02 | 2013-12-04 | 威海市妇女儿童医院 | Oral care liquid for preventing chemotherapy-induced oral mucositis |
-
2001
- 2001-02-27 CN CN 01104489 patent/CN1126558C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1310011A (en) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101129817B (en) | Chinese medicine formulation for treating hypertension and method of producing the same | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN1840128A (en) | Medicine for treating cardiovascular disease | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN101856405A (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN101637548B (en) | Medicine for treating kidney stone and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN1150016C (en) | Medicine for treating fever caused by lupus erythematosus and other immunological disease | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus | |
| CN1063077C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing same | |
| CN1281252C (en) | Medicinal composition for treating urinary lithiasis and its preparing method | |
| CN1602921A (en) | Medicine for treating diabetes and its preparing process | |
| CN1148969A (en) | Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN1352979A (en) | Chinese medicine for replenishing vital energy and promoting blood circulation | |
| CN1481874A (en) | Capsule for fortifying kidney and nourishing qi and its preparation mehtod | |
| CN1314175A (en) | Traditional Chinese medicine composition for curing insomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Ding Congli Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031105 Termination date: 20200227 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |